Uncategorized

Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor

Published

on

Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version